September is Pulmonary Fibrosis Awareness Month, and advocates around the globe are joining together to shine a light on PF ...

The U.S. Food and Drug Administration put a novel inhaled therapy for pulmonary fibrosis with no known cause on a ...

After a recent trip, columnist Kylene Henderson and her husband now know what to look for when vacation planning with ...

A move to a new house is closer than it appeared to be, but columnist Sam Kirton doesn't object, even though it will be a lot ...

Columnist Sam Kirton didn't pay attention to his lab results, even after his PF diagnosis, but that changed after a recent ...

The U.S. Food and Drug Administration (FDA) has granted its orphan drug designation to Alentis Therapeutics’ antibody-based therapy lixudebart (ALE.F02) for idiopathic pulmonary fibrosis (IPF). Orphan ...

The inhaled therapy MNKD-201 was tolerated well in people with idiopathic pulmonary fibrosis (IPF) in a Phase 1 clinical trial, and a Phase 2 study to further test it is underway, the treatment’s ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating its idiopathic pulmonary fibrosis (IPF) treatment bexotegrast due to safety issues. The BEACON-IPF (NCT06097260) ...

The oral therapy Jascayd (nerandomilast) has been approved in the European Union for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The marketing ...

CS014, a treatment candidate for idiopathic pulmonary fibrosis (IPF), was found to be safe and well tolerated in healthy volunteers in a Phase 1 clinical trial, according to new data from developer ...

Besides medication that can help manage symptoms and slow the progression of pulmonary fibrosis (PF), there are other therapeutic strategies available that can help patients cope with the effects of ...